Advanced search
Publication Cover
Leukemia & Lymphoma Volume 62, 2021 - Issue 3
Submit an article Journal homepage
128
Views
1
CrossRef citations to date
0
Altmetric
Letters to the Editor

Curative surgery in highly selected patients with heavily pretreated, relapsed/refractory classical Hodgkin lymphoma

Vassilios Papadakisa Department of Pediatric Hematology- Oncology, Agia Sofia Children's Hospital, Athens, Greece
,
Maria Efstathopouloub Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece
,
Maria K. Angelopouloub Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece
,
Gerassimos Tsourouflisc Second Department of Surgery, Propedeutic, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece
,
Vassilios Prassopoulosd Department of Nuclear Medicine, HYGEIA Hospital, Athens, Greece
,
Phivi Rondogiannie Department of Nuclear Medicine and PET/CT, Evangelismos General Hospital, Athens, Greece
,
Antonios Kourtesisf Department of Pediatric Cardiac Surgery, Agia Sofia Children's Hospital, Athens, Greece
,
Sophia Polychronopouloua Department of Pediatric Hematology- Oncology, Agia Sofia Children's Hospital, Athens, Greece
,
Gerassimos A. Pangalisb Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, Greece;g Department of Hematology, Athens Medical Center, Athens, Greece
&
Theodoros P. Vassilakopoulosb Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, Athens, GreeceCorrespondence[email protected] [email protected]
 show all
Pages 722-726 | Received 29 Aug 2020, Accepted 20 Oct 2020, Published online: 25 Nov 2020

References

  • Canellos GP, Rosenberg SA, Friedberg JW, et al. Treatment of Hodgkin lymphoma: a 50-year perspective. J Clin Oncol. 2014;32(3):163–168.
  • Vassilakopoulos TP, Angelopoulou MK. Advanced and relapsed/refractory Hodgkin lymphoma: what has been achieved during the last 50 years. Semin Hematol. 2013;50(1):4–14.
  • Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol. 2012;30(18):2183–2189.
  • Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the Multicohort Single-Arm Phase II CheckMate 205 Trial. J Clin Oncol. 2018;36(14):1428–1439.
  • Chen R, Zinzani PL, Fanale MA, KEYNOTE-087, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma. J Clin Oncol. 2017;35(19):2125–2132.
  • Borchmann S, von Tresckow B. Novel agents in classical Hodgkin lymphoma. Leuk Lymphoma. 2017;58(10):2275–2286.
  • Vassilakopoulos TP, Chatzidimitriou C, Asimakopoulos JV, et al. Immunotherapy in Hodgkin lymphoma: present status and future strategies. Cancers (Basel). 2019;11(8):1071.
  • Lazarovici J, Dartigues P, Brice P, et al. Nodular lymphocyte predominant Hodgkin lymphoma: a lymphoma study association retrospective study. Haematologica. 2015;100(12):1579–1586.
  • Savage KJ, Mottok A, Fanale M. Nodular lymphocyte-predominant Hodgkin lymphoma. Semin Hematol. 2016;53(3):190–202.
  • Mauz-Körholz C, Gorde-Grosjean S, Hasenclever D, et al. Resection alone in 58 children with limited stage, lymphocyte-predominant Hodgkin lymphoma-experience from the European network group on pediatric Hodgkin lymphoma. Cancer. 2007;110(1):179–185.
  • Appel BE, Chen L, Buxton AB, et al. Minimal treatment of low-risk, pediatric lymphocyte-predominant hodgkin lymphoma: a report from the Children's Oncology Group. J Clin Oncol. 2016;34(20):2372–2379.
  • Lacher M. Role of surgery in Hodgkin's disease. N Engl J Med. 1963;268:289–292.
  • Badar T, Epperla N, Szabo A, et al. Trends in postrelapse survival in classic Hodgkin lymphoma patients after experiencing therapy failure following auto-HCT. Blood Adv. 2020;4:41–54.
  • Tsirigotis P, Vassilakopoulos T, Batsis I, et al. Positive impact of brentuximab vedotin on overall survival of patients with classical Hodgkin lymphoma who relapse or progress after autologous stem cell transplantation: a nationwide analysis. Hematol Oncol. 2018;36(4):645–650.
  • Fahy AS, Kong I, Weitzman S, et al. A role for surgery in the treatment of relapsed Hodgkin lymphoma. Pediatr Blood Cancer. 2019;66(1):e27402.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.